The OR of MVMR suggests that a one-SD increase in ApoA-1 is associated with a 24.00% reduction in the risk of insomnia (Table 2, ApoA-1, OR: 0.7600, 95% CI: 0.6362–0.9079, P = 0.002). Here, APOA1 is linked to insomnia.